Table 5.
Distribution characteristics of sIgE and tIgE in different populations.
| CU | AD | AR | AS | P a | |
|---|---|---|---|---|---|
| Group1 sIgE (+) tIgE (+) |
94 (23.7) | 159 (38.7)* | 48 (47.5)* | 47 (33.8) | <0.001 |
| Group2 sIgE (+) tIgE (-) |
37 (9.3) | 54 (13.1) | 17 (16.8) | 20 (14.4) | 0.112 |
| Group3 sIgE (-) tIgE (+) |
100 (25.3) | 61 (14.8)* | 7 (6.9)* | 17 (12.2)* | <0.001 |
| Group4 sIgE (-) tIgE (-) |
165 (41.7) | 137 (33.3) | 29 (28.7)* | 55 (39.6) | 0.024 |
CU, chronic urticaria; AD, atopic dermatitis; AR, allergic rhinitis; AS, asthma.
a
Pearson chi-squared test.
*Bonferroni correction was used for post-hoc analysis. Compared with the CU group, P<0.0167 (0.05/3) was considered statistically significant.